How we think about Physical AI
Main Sequence sets out its investment thesis for physical AI, describing portfolio companies across robotics, vision, connectivity, compute and simulation, and recalling over $100 million invested since inception.
Startup · $10m raised · AI · Robotics
An AI startup building 'Windows for robots', an operating system for AI agents sitting underneath large language models.
Every investor coverage indicates participated in a round Metacognition AI raised.
| Investor | Rounds | Invested |
|---|---|---|
| Main Sequence Ventures | Pre-seed | - |
Companies Metacognition AI acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Stephen Gould | Founder | SmartCompany, Startup Daily, Forbes Australia, Dealroom |
| Paul Dalby | Founder | SmartCompany, Startup Daily, Forbes Australia, Dealroom |
| Anton van den Hengel | Founder | SmartCompany, Startup Daily, Forbes Australia, Dealroom |
Stories naming Metacognition AI. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Main Sequence sets out its investment thesis for physical AI, describing portfolio companies across robotics, vision, connectivity, compute and simulation, and recalling over $100 million invested since inception.
Data page reporting Visaible.ai's $1 million seed raise from August 2026; the Sydney hotel-booking platform's founder Sam Rich previously worked at Bain and Goldman Sachs.
Roundup of four trans-Tasman raises: First Table, Metacognition AI, Dela and GoTroppo secured a combined $21.5 million for restaurant discounting, robotics software, scam-safe payments and flexible internet plans.
Australian biotech ENA Respiratory, whose INNA-051 nasal spray targets respiratory viruses, has been granted $2.98 million via the Biointelect Venturer program to fund a trial in adults with asthma.
Datapile logs an $8.6 million raise by Sydney vascular-ultrasound startup Vexev, led by TreeArc Investment Group with TEN13 among four backers, earmarked for regulatory approval and clinical rollout.
Also datapile.co·Startup Daily·SmartCompany·Dealroom·Forbes Australia·fundedstartupsdaily.com